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CHAPTER I 
INTRODUCTION 
Chromium is an essential trace element for animals and 
humans. Evaluation of chromium status in humans is· 
difficult because circulating chromium may not be in 
equilibrium with tissue stores. Chromium measurement 
requires careful sample handling and sophisticated 
instrumentation (1). Due to th~se limitations, relatively 
few data are available on chromium intake, absorption and 
excretion in humans. Data on drug-chromium interactions are 
not available. 
Significance of the Problem 
Chromium intake varies widely. Estimated chromium 
intake ranged from 24.5 ~gjday in England (2), 29 ~gjday in 
Finland (3), 56 ~gjday in Canada (4), to 240 ~gjday in 
Belgium (5). In more recent international studies intakes 
below 100 ~gjday were reported (6). In the United States 
estimated mean chromium intake ranged from 25-89 ~gjday (7, 
8} compared to the safe and adequate daily dietary intake of 
50-200 ~g per day (9). 
Processing and refining usually reduced chromium in 
foods (10, 11} with estimates of chromium losses of up to 80 
1 
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percent for some foods (11). Consumption of highly 
processed foods may result in marginal chromium intake and 
depletion of chromium stores. The elderly are at particular 
nutritional risk because of their reduced energy needs and 
decreasing absorptive capacities. studies of chromium 
supplementation in elderly subjects (12, 13) suggested that 
u.s. dietary intakes may be inadequate to maintain tissue 
chromium levels throughout life. 
Insufficient chromium intake may be responsible for 
some of the glucose intolerance associated with aging (14, 
15). The long-term suboptimal chromium intake may cause the 
decrease in tissue chromium with age and contribute to the 
incidence of non-insulin dependent diabetes and 
atherosclerosis observed in the United States (16). 
The elderly may be particularly at risk for adverse 
drug-nutrient interactions because of their chronic use of 
medications. Gastrointestinal disorders may promote antacid 
abuse in the elderly. Many post-menopausal women take 
calcium-based antacids such as Tums to increase their 
calcium intake. Antacid preparations are commonly prescribed 
in order to reduce gastrointestinal blood loss associa-ted 
with aspirin therapy in the treatment of arthritis. 
Additionally, many commercially available aspirin 
formulations contain antacids (i.e.; Bufferin). 
Advertising further encourages over-the-counter drug abuse. 
These trends may exacerbate existing problems associated 
with marginal dietary intake of chromium in humans. 
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This study was designed to evaluate the effects of 
distilled water (control), Tums, Maalox, vitamin c, aspirin 
and Bufferin on absorption, retention and excretion of 
51chromium from 51crcl3 in female rats. 
Objective 
The following research objective was developed for the 
proposed study: 
1. to determine if selected over-the-counter drugs 
(Tums, Maalox, vitamin c, aspirin and Bufferin) 
alter absorption, retention or urinary excretion of 
5lcr from 5lcrcl3 in female rats. 
Hypothesis 
The following hypothesis was developed for this study: 
1. There will be no·statistically significant 
differences in absorption, retention or urinary 
excretion of 51chromium from 51crc13 due to a dose 
of distilled water, Tums, Maalox, vitamin c, 
aspirin, or Bufferin. 
Limitations 
This study involved a single therapeutic dose of Tums, 
Maalox, vitamin c, aspirin and Bufferin. Thus, the long 
term effects of these drugs were not explored. The 
pharmacodynamics of many drugs are dose-dependent. Dosage 
form characteristics as well as a range of concentrations 
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were not investigated. Thus, the data we obtained, while 
significant, are not generalizable due to the single dose. 
Another limitation is the use of an animal model rather than 
human subjects. 
CHAPTER II 
REVIEW OF LITERATURE 
Over-the-Counter Drug Interactions in the Elderly 
A Brief History of Aspirin 
Man's practice of self-medication is deeply embedded in 
history. Around 400 B.C. Hippocrates suggested that women 
should drink an extract from the leaves of the willow tree 
to lessen the pain of childbirth (17). In the 19th century 
the active agent from the willow tree was identified as 
salicylic acid. In 1860 salicylic acid was synthetically 
manufactured but unpatentable due to its extreme 
gastrointestinal irritation with continuous use. In 1900 
the derivative acetylsalicylic acid which is less irritating 
was synthesized and patented by Farbenfabriken Bayer, 
founder of the Bayer company (18). Since the early 20th 
century aspirin has been used in clinical medicine in 
reducing pain, fever, and inflammation. 
Clinical Uses of Aspirin 
In recent years, results of some studies have suggested 
that aspirin might prevent heart attacks and strokes (19-
26), slow the formation of cataracts (27-33), and perhaps 
5 
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even diminish the incidence of pregnancy-induced 
hypertension and pre-eclampsia (34-36). At the same time, 
many clinicians have urged that children with flu or chicken 
pox not be given aspirin because such children may face an 
increased risk of Reye's syndrome, which can be fatal (37-
38). More recently, salicylates have been implicated in 
Reye's syndrome in adults (40-41). Data linking aspirin to 
gastrointestinal ulceration and gastrointestinal bleeding 
have emerged as well ·(42-44). 
Aspirin is most frequently taken to lessen pain, lower 
fever, or reduce inflammation of arthritis and rheumatic 
fever. Rheumatoid arthritis, found among all age groups, 
affects at least 6.5 million Americans. Women are affected 
about three times as frequently as men (17, 39, 45). 
Although rheumatoid arthritis is more severe, it is not as 
common as osteoarthritis. The latter is more degenerative 
than inflammatory and mainly affects the body's weight-
bearing joints (spine, hips and knees). At least 16 million 
Americans need medical care for osteoarthritis. Over age 
45, osteoarthritis prevalence is greater in women than men 
(17, 39, 45, 46). 
Despite the introduction of newer non-steroidal anti-
inflammatory drugs, aspirin remains the drug of choice or at 
least the initial drug for treatment of both arthritic 
conditions (17, 45). According to the July, 1982, Consumer 
Reports, arthritis sufferers "consume about half of all 
aspirin sold". However, because high doses of aspirin are 
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required in the treatment of arthritis, the side effects of 
the drug, especially irritation of the stomach, can become a 
major problem for some patients. 
The Gastric Barrier and Aspirin 
Absorption from the stomach is normally very limited. 
This low level of absorption is mainly attributed to highly 
resistant mucosal cells that secrete a viscid and adherent 
mucus and the very tight junctions between the adjacent 
epithelial cells that line the gastric mucosa (47). 
Competent tight junctions prevent diffusion of contents of 
the gastric lumen between the mucosal cells into the 
interstitial fluid. 
The gastric mucosal barrier has physiochemical 
properties similar to those of all other cells; it is a 
lipid and protein layer penetrated by very few water-filled 
channels. In contrast with water-soluble molecules, which 
are restricted to water filled channels, fat-soluble 
compounds can cross a lipid-containing membrane by 
dissolving in the lipid. Consequently, some compounds are 
water soluble at one pH and fat-soluble at another. Aspirin 
(acetylsalicylic acid) is an example. Aspirin has a pKa of 
3.5. When the drug is dissolved in a solution whose pH is 
higher than 3.5, more than half the carboxyl groups are 
ionized, and at pH 6 virtually all the salicylate molecules 
are negatively charged. In this state (negatively charged 
at pH 6), the molecules are water soluble, and their passage 
8 
across the mucosa is restricted to water-filled channels. 
When aspirin is dissolved in a solution with a pH below 3.5 
it is un-ionized and fat soluble; it then dissolves in the 
lipid-protein layer and is rapidly absorbed from acid 
gastric contents (48). 
Aspirin damages the gastric mucosal barrier as it is 
absorbed. Davenport (49) hypothesized that the aspirin 
disrupts the lipid-protein layer on the surface of the 
cells, and it causes desquamation by breaking the tight 
junctions between cells. As a consequence, the mucosa 
becomes abnormally permeable to water-soluble compounds and 
ions. Hydrogen ions move rapidly through the damaged 
barrier,_ and their flow is facilitated by exchange for 
sodium. Entry of hydrogen ions into the mucosa exacerbates 
damage caused by the aspirin and destruction of the mucosa 
follows. Potassium and organic cell contents enter the 
lumen, followed by sodium and chloride from the interstitial 
fluid. Upon further destruction of barriers, a fluid 
containing glucose and plasma proteins flows from the 
interstitial spaces and capillaries. When the mucosa is 
damaged it also releases histamine. Histamine is a 
vasodilator, and it increases capillary permeability. Both 
effects promote capillary filtration; consequently 
interstitial volume and pressure rise, and fluid is forced 
through the relatively larger channels opened by mucosal 
injury. Aspirin opens the gates of the mucosal barrier, and 
acid pouring through the breached defenses destroys 
capillaries and venules. Finally, after the most severe 
damage, bleeding occurs. 
Aspirin and Antacid Interactions 
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In an attempt to ameliorate deleterious effects on the 
gastroduodenal mucosa, numerous modifications in aspirin 
administration have been studied. These have included 
administration of aspirin in an enteric-coated form, 
buffered, or simultaneous administration of antacids,· 
cimetidine or prostaglandins to reduce the gastric 
absorption and irritation of aspirin (50-52). 
Addition of an antacid to aspirin therapy results in a 
"buffer zone" of increased pH immediately around the 
dissolving aspirin particles. This buffer-zone enhances the 
dissolution of the aspirin particles and decreases the local 
irritation by the undissolved aspirin particles. More rapid 
absorption and higher peak levels in the blood were achieved 
with the administration of commercially available 
effervescent tablets, the soluble salt of aspirin, sodium 
acetylsalicylate, and preparations containing aluminum and 
magnesium buffers than with standard preparations of aspirin 
(53). Also aspirin from an enteric coated preparation was 
absorbed more rapidly when given concomitantly with an 
aluminum hydroxide-magnesium hydroxide combination antacid 
(50) . 
Gaspari et al. (54) found that.both aluminum hydroxide-
magnesium hydroxide and calcium carbonate containing 
10 
antacids modify oral aspirin pharmacokinetics in uremic 
patients on hemodialysis. The lower plasma aspirin 
concentrations associated with antacids in uremic patients, 
however, were the consequence of a slow absorption rate, 
rather than of rapid hydrolysis in the circulation. The 
potential chemical interactions between aluminum ions 
released by the antacids and the aspirin molecule may 
explain the results obtained with the aluminum-containing 
antacids. Aspirin reportedly formed a water- insoluble 
complex with aluminum making the limiting step for 
absorption the rate of release of free acid from the 
complex. Levy and Sahli (55) confirmed that the aluminum 
salt of acetylsalicylic acid was absorbed more slowly than 
the acid form of the drug. 
Hogben et al. (56) demonstrated in detail that drugs 
that are weak electrolytes may be quickly absorbed from acid 
gastric contents if they are un-ionized and fat soluble in 
acid solution. For example, at pH 2, acetylsalicylic acid 
(PKa 3.5) is more than 95 percent in the un-ionized, fat 
soluble form, and it diffuses readily across the mucosa. At 
pH 7 acetylsalicylic acid is completely ionized and fat 
insoluble; it is poorly absorbed from the stomach. This 
could explain the interference between the aspirin and 
calcium carbonate since aspirin absorption is partially pH 
dependent. However, other data indicated that buffered 
solutions of aspirin were as completely and rapidly absorbed 
as unbuffered solutions (57-58). More rapid emptying of the 
buffered solutions into the duodenum and the resultant 
larger absorptive area supposedly compensated for the 
reduced gastric absorption. 
Cytoprotection by Prostaglandins 
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Prostaglandins also may be useful for preventi.ng or 
reducing aspirin-induced mucosal damage. Prostaglandins are 
distributed widely throughout the gastrointestinal tract and 
influence a number of gastric and intestinal functions. 
Robert and coworkers (59) reported that certain 
prostaglandins prevented experimental damage to gastric 
mucosa by a variety of noxious agents, including aspirin. 
In initial clinical studies, oral administration of 1.0 
mg of prostaglandin E2 (PGE2) four times daily before 
aspirin ingestion prevented increased fecal blood losses in 
healthy volunteers (60). In another study, aspirin-induced 
upper gastrointestinal blood loss, measured by serial 
gastric washing, was decreased (p<0.05) during the second 
day after administration of PGE2 (51). Gilbert and 
colleagues (61) indicated that prostaglandin pretreatment 
prevented endoscopically visible severe gastric mucosal 
injury after single-dose aspirin administration. 
The physiologic mechanisms by which prostaglandins 
protect the gastric mucosa from damage by non-steroidal 
anti-inflammatory drugs are not known. The chief 
cytoprotective role of prostaglandins may be to increase the 
secretion of mucus (62). Other hypotheses have included 
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activation of gastric mucosal adenyl cyclase, alteration of 
gastric mucosal blood flow or tightening of the gastric 
mucosal barrier; however, these hypotheses for protective 
effects remain speculative (63-66). 
Antacids 
Antacids are commonly prescribed by clinicians for 
treatment of peptic ulcers, reflux esophagitis and 
hyperchlorhydria. Antacids enhanced healing of ulcers to 
the same degree as other active drugs. Initially, the 
efficacy OF antacids was demonstrated at high doses. Recent 
studies have indicated that dose·s with low neutralizing 
capacity promote ulcer healing (67, 68). This raises the 
question of whether the mechanism of action actually 
involves neutralization of the luminal acid. 
Cytoprotection by Antacids 
Aluminum hydroxide may be cytoprotective. Szelenyi et 
al. (69) and Tarnawski et al. (70) reported an increased 
concentration of prostaglandin E2 (PGE2) in the gastric 
contents of rats after intragastric administration of high 
doses of antacids containing aluminum hydroxide and 
magnesium hydroxide. An elevated PGE2 concentration in the 
gastric juice may indicate increased gastric synthesis of 
PGE2 and enhanced cytoprotective activity (71, 72). 
Confirming previous observations by Szelenyi et al. 
(69) and Tarnawski et al. (70), Berstad et al. (73) noted 
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increased intraluminal concentration of PGE2 in response to 
intragastric administration of both high and low doses of 
aluminum-hydroxide-containing antacids. Low doses of 
antacids, comparable to therapeutic low dose regimens in 
man, also increased the concentration of PGE2 in the gastric 
content. 
If increased intraluminal PGE2 concentration reflects 
increased mucosal synthesis of PGE2, antacids not only may 
neutralize gastric acid but also may stimulate mucosal PGE2 
synthesis. A high dose of aluminum hydroxide released more 
PGE2 when given alone than when given in an antacid mixture 
with magnesium hydroxide and calcium carbonate. These 
results_support the concept proposed by Szelenyi et al. that 
PGE2 release was a specific effect of aluminum hydroxide and 
not a general effect of antacids (69). 
Self-prescription of Antacids 
The majority of antacids consumed are obtained over-
the-counter (OTC) or "self-prescribed" for treatment of 
either the occasional "upset" stomach or a variety of other 
symptoms (74). However, "heartburn" and "indigestion" may 
indicate ischemic heart disease rather than a 
gastrointestinal disorder. Temporary relief from OTC 
medications often gives the patient a false sense of 
security and delays appropriate medical intervention (75). 
Excessive use of aspirin, antacids and other over-the-
counter drugs without medical supervision may be dangerous. 
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Abuse of OTC drugs may be most detrimental to the elderly 
because they consume a disproportionately high percentage of 
all drugs. In 1982, only 8% of the population was 70 years 
or older, yet this age group used 22% of all drugs (76). 
These data may underestimate drug consumption because 
reports used by the Food and Drug Administration (~DA) did 
not include all outlets for over-the-counter drugs. Data 
were limited to the hospital and drug store markets which 
may represent only 40% of total sales for a drug such as 
aspirin (76). 
In 1986, approximately 11.7% of the population were 65 
or older; yet, 31% of all drugs were prescribed for this age 
group. Seventy-five percent of the population over 65 also 
reported using non-prescription or over-the-counter drugs 
(77). These data represent an increase in the population 65 
and older as well as an increase in their chronic drug 
consumption. 
Frequently, the elderly patient does not inform or 
consult the physician regarding concomitant self-medication 
with OTC products (78). Guttman (79) found that only 12% of 
the elderly patients using OTC drugs had consulted a 
physician about their use. Also clinicians frequently fail 
to document reported OTC usage by the elderly patient (80). 
Chaiton and colleagues (81) found that nearly 60% of an 
elderly study population used OTC drugs, with women using 
them more often than men. Guttman (79) found that two-
thirds of elderly ambulatory patients used OTC drugs. More 
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than 50% of these drugs were oral analgesics. In another 
sample of 244 people more than 60 years of age, analgesics 
were most commonly used (66.6%), followed by cardiovascular 
agents (33.5%), laxatives (30.6%), vitamins (29.3%), 
antacids (26.4%) and anti-anxiety agents (22.3%) (82). 
Forty percent of the total medications taken were OTC drugs. 
Eighty-three percent of these clients were also taking two 
or more drugs. The most common drugs used by women were 
sedative-tranquilizers, followed by hormones and 
gastrointestinal agents. The most frequent categories in 
men were analgesics, sedative-tranquilizers and 
cardiovascular drugs. 
Because OTC drugs are easily purchased, most people 
regard them as harmless. However, the simultaneous use of 
OTC drugs with other prescribed drugs may result in side 
effects or toxicity (77, 78, 83-85). "Of more than 4,000 
drug abuse studies of elderly patients between 1926 and 
1975, 10% dealt with adverse pathologic and physiologic 
effects from inappropriate OTC usage" (75). Aspirin was 
cited most often, but antacids and other OTC drugs were 
implicated as well. 
Aspirin-Drug Interactions 
Adverse effects from aspirin are not common but the 
frequency with which aspirin is taken, alone or in multiple-
drug compounds explained its repeated involvement (86-88). 
Aspirin inhibits the uricosuric effects of probenecid and 
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sulfinpyrazone, may enhance the hypoglycemic effects of 
sulfonylureas, decreases both clearance and plasma protein 
binding of methotrexate thereby increasing the drug's 
toxicity, and may cause an increased risk of hemorrhage when 
taken with prescription anticoagulants such as warfarin (75, 
89) • 
Antacid-Drug Interactions 
Antacids may result in slow or incomplete absorption, 
may have no effect on drug absorption, or may increase the 
rate or amount of drug absorbed resulting in toxicity. The 
most clinically significant adverse effect of antacids is 
the decreased absorption of drugs such as iron, 
tetracyclines, cimetidine (Tagament), and digoxin (Lanoxin) 
(90). In addition, antacids may increase the pH of the 
urine and therefore influence the elimination kinetics of 
other drugs (91). Because of the variability among 
individuals, predicting the effect of an antacid on 
absorption of a particular drug can be difficult. 
Drug-Induced Hospitalizations 
The Royal College of Physicians estimated that adverse 
drug reactions were responsible for 20 to 25 percent of all 
elderly patient admissions to acute- care hospitals in 
England (92). In the United States, adverse reactions in 
the elderly account for between 12 and 17 percent of 
hospital admissions (78). 
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canadian data indicated that 30 percent of all elderly 
patients admitted to acute-care facilities from nursing 
homes suffered from adverse reactions to drugs, while 
British studies suggested that 40 percent of elderly persons 
living in the community were affected by adverse drug 
reactions {77). The use by the elderly of a greater number 
of drugs increases the probability of adverse reactions. 
The frequency with which OTC drugs were responsible for 
illnesses leading to hospitalization emphasizes the fact 
that OTC medicines,. alone or in combination with 
prescription drugs can produce severe reactions. 
Advertising and over-The-Counter Drugs 
Over-the-counter {OTC) drugs used knowledgeably can 
contribute to the well-being of the elderly. Unfortunately, 
statements made in advertising are not necessarily accurate. 
Even quotations taken from published reports and clinical 
studies can be taken out of context thereby misleading the 
consumer. Possible beneficial effects of a drug or product 
are often publicized long before they are confirmed. 
Examples of this include oat bran to lower cholesterol, 
Metamucil to increase dietary fiber, Turns as a calcium 
supplement and aspirin in the prevention of heart attacks. 
Thus, the elderly should seek knowledgeable and unbiased 
advice about drug regimens. 
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Drug-Nutrient Interactions 
Data indicate that health, social and economic problems 
of the elderly, especially those over age 75, are 
predominantly the problems of women. Furthermore, old age 
is associated with women living alone on reduced incomes and 
in increased poverty, accompanied with a greater risk of ill 
health, institutionalization, and death (89). 
Elderly women consume a greater percentage of all drugs 
than men. Many elderly people, primarily women with 
osteoporosis or those fearing osteoporosis, take calcium 
supplements either as calcium lactate, calcium carbonate or 
calcium gluconate. Many calcium supplements release calcium 
ions that are absorbed and can cause clinically important 
hypercalcemia, rebound acid hypersecretion, constipation, 
and a variety of other interactions. 
Adverse metabolic and nutritional effects of antacid 
abuse in the elderly are eloquently and extensively reviewed 
by Roe (83-85). Briefly, hypophosphatemia has been reported 
with excessive use of aluminum and magnesium hydroxide 
containing antacids, while aluminum containing antacids are 
associated with increased intestinal and urinary excretion 
of calcium. Additionally, magnesium intoxication was 
reported in patients with chronic renal failure who took 
magnesium containing antacids. 
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Conventional doses of antacids normally cause few 
adverse reactions. However, frequent and prolonged use with 
larger doses becomes more significant. 
Drug-Mineral Interactions 
Freeman and Ivy (94) reported that calcium carbonate 
and aluminum hydroxide reduced the retention of iron fed to 
anemic rats, while other researchers have reported decreased 
absorption of iron after administration of antacids to 
normal subjects (95). Uncoated aspirin caused iron-
deficiency anemia in the elderly by inducing blood loss from 
the gastrointestinal tract (83, 89). 
Commonly used OTC drugs (as well as prescription drugs) 
can affect mineral status and have the most impact on 
minerals that are marginal in the diets of the elderly. 
Impaired absorption of nutrients in the elderly has been 
reported (96). Chromium is an essential trace element for 
animals and humans. Insufficient dietary chromium leads to 
signs and symptoms similar to those associated with diabetes 
andjor cardiovascular diseases (97). 
The dietary chromium intake of normal individuals is 
often less than the suggested minimum intake. Recent 
studies (7, 8, 98, 99) have estimated mean chromium intake 
in the United States to be 25-89 ugjday compared to the 
estimated safe and adequate daily dietary intake of 50-200 
ug per day (9). Dietary chromium is not readily absorbed 
(98, 100-101). 
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Unfortunately, data on drug-chromium interactions are 
not available. Because chromium is essential, is not 
readily absorbed, and tends to be low in the average 
American diet, the effects of commonly used drugs (both 
prescription and OTC) on chromium absorption need to be 
investigated. 
In this study, adult female rats were used to determine 
the effects of several commonly used over-the-counter drugs 
on 51chromium absorption, retention and excretion from 
51crc13. Because circulating chromium may not be in 
equilibrium with tissue stores, its measurement in humans is 
difficult. Also, the low concentrations in biological 
samples require careful sample handling and sophisticated 
instrumentation for accurate measurement (1). Thus, the use 
of a radioactive isotope of chromium in an animal model 
allows more sensitive evaluation of drug-chromium 
interactions. 
CHAPTER III 
EFFECTS OF OVER-THE-COUNTER DRUGS ON 
CHROMIUM ABSORPTION IN RATS 
Melissa L. Davis, Carol D. Seaborn, and 
Barbara J. Stoecker 
Department of Food, Nutrition and Institution Administration 
Oklahoma State University 
Stillwater, Oklahoma 74078 
ABSTRACT 
Effects of five over-the-counter drugs on absorption 
and retention of 51chromium from 5lchromium chloride 
c51 crcl3) were evaluated using adult female rats. In 
addition to the control group given qistilled water (pH 
7.89), groups were given vitamin C (5 mg, pH 2.76), Turns (40 
mg, pH 9.72), Maalox (40 mg, pH 8.39), aspirin {40 mg, pH 
2.74) or Bufferin (40 mg, pH 8.73). 
After a 12 h fast, the drugs were administered by 
gastric intubation (0.5 ml) followed immediately by an oral 
dose of 5lcrcl3 (55 ~Ci) in 0.14 M HCl (50 ~1). Urine and 
blood samples from the tail were collected at intervals. 
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Twelve hours after dosing animals were anesthetized and 
exsanguinated. At 12 h 51cr in blood, urine and tissues was 
higher (p<0.0001) in the aspirin group than in other groups. 
The group given Maalox had lower (p<0.0001) 51cr in blood, 
urine and tissues than the other groups. The Tums group was 
lower (p<0.0001) than all except the Maalox group •. 
Increased 5lcr absorption in the aspirin group and decreased 
51cr absorption in the Maalox group did not appear to be 
mediated solely by pH. Potential effects on Cr status of 
long-term use of aspirin or antacids need evaluation because 
over-the-counter drugs may alter Cr absorption. 
INDEXING KEY WORDS: Chromium, vitamin c, aspirin, antacids, 
rats and absorption. 
INTRODUCTION 
Chromium is an essential trace element for animals and 
humans. Evaluation of chromium status in humans is 
difficult because circulating chromium may not be in 
equilibrium with tissue stores (1). Due to these 
limitations, relatively few data are available on chromium 
intake, absorption and excretion in humans. 
Chromium intake varies widely. Chromium intakes below 
100 ugjday were reported in recent international studies 
(2). In the United States estimated mean chromium intake 
ranged from 25-89 ugjday (3, 4) compared to the safe and 
adequate daily dietary intake of 50-200 ug per day (5). 
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Processing and refining reduced chromium in foods with 
estimates of chromium losses of up to 80 percent for some 
foods (6). Consumption of highly processed foods may result 
in marginal chromium intake and depletion of chromium 
stores. The elderly are at particular nutritional risk 
because of their reduced energy needs and decreasing 
absorptive capacities. Insufficient chromium intake may be 
responsible for some of the glucose intolerance associated 
with aging (7, 21). Furthermore, long-term suboptimal 
chromium intake may contribute to the incidence of non-
insulin dependent diabetes and atherosclerosis observed in 
the United States (8). 
The. elderly may be particularly at risk for adverse 
drug-nutrient interactions because of their chronic use of 
medications (9-10). Gastrointestinal disorders may promote 
antacid abuse in the elderly. Many post-menopausal women 
take calcium-based antacids such as Tums to increase their 
calcium intake. Antacid preparations are commonly 
prescribed in order to reduce gastrointestinal blood loss 
associated with aspirin therapy in the treatment of 
arthritis. Additionally, many commercially available aspirin 
formulations contain antacids (i.e.; Bufferin). Interactions 
of antacids and minerals have not been thoroughly 
investigated. However, several studies reported that. 
antacids reduced absorption of iron and zinc (11, 12, 19, 
20). Vitamin C enhances iron absorption but its effects on 
chromium absorption need further investigation. Data on 
chromium and drug-interactions are not available. 
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Aspirin is one of the most widely used drugs. In 
recent years, results of some studies have suggested that 
aspirin might prevent heart attacks and strokes (13-18). 
More recently, the media have focused on aspirin and its use 
in preventing heart attacks and strokes. Thus, aspirin use 
by the public and especially by the elderly may increase. 
Advertising further promotes over-the-counter drug use. 
The measurement of chromium in humans is 
difficult.Thus, use of a radioactive isotope of chromium in 
an animal model allows the sensitive evaluation needed to 
determine possible drug-chromium interactions. The present 
study was designed to determine the effects of distilled 
water, Turns, Maalox, vitamin c, aspirin or Bufferin on 
Slchromium absorption, retention and excretion in female 
rats. 
MATERIALS AND METHODS 
Forty-six female Sprague Dawley rats (Sasco, Inc., 
Omaha, NE) with a mean weight of 278±5 g were randomly 
assigned to six treatment groups. All animals were 
acclimatized to the animal care facilities before use. 
Prior to the experiment, rats were fasted overnight (12 h) 
but allowed access to water. Animals were intubated with 
0.5 ml of distilled water (pH 7.89), or 
solutions/suspensions of Turns (40 mg, pH 9.72), Maalox (40 
25 
mg, pH 8.39), vitamin c (5 mg, pH 2.76), Bayer aspirin (40 
mg, 2.74), or Bufferin (40 mg, pH 8.73). Immediately after 
gastric intubation, animals were fed 50 ~1 of Slchromium 
chloride (55 ~Ci) in (0.14 M) HCl by micropipette. Animals 
were then placed in individual metabolic cages for urine 
collection. 
Approximately 0.5 ml of blood was collected from the 
tail.at 45 min, 1.5 h, 3 h, and 6 h after intubation of the 
test substance and 51chromium chloride. At 3, 6 and ·12 hrs 
urine samples were carefully collected to avoid 
contamination with feces. Twelve hours after gastric 
intubation, rats were anesthetized with ketamine HCl (30 
mgjkg) and xylazine (2.2 mgjkg) and exsanguinated. Blood, 
urine and tissues were sampled and counted in a gamma 
counter to assess 51 chromium chloride absorption, retention 
and excretion. 
Total 51 chromium chloride in blood was estimated 
assuming blood was 7% of body weight. 51chromium chloride 
in each tissue and in blood and urine was expressed as 
percent of the Slchromium dose. Data were analyzed using 
the Statistical Analysis System (SAS). Log transformations 
were performed on blood and urine data and square root 
transformations on tissue data to correct for non-homogenity 
of variance. The general linear model (GLM) procedure in 
SAS was used for analysis of variance of the transformed 
tissue and urine data. A repeated.measures analysis was 
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performed on the blood data. Differences among means were 
identified using the least significant difference test. 
RESULTS 
In blood, animals intubated with aspirin had higher 
(p<0.0001) 51chromium than animals given any other test 
substance, while the Maalox group had lower (p<0.0001) 
51chromium than all other test substances (Figure 1). The 
Tums group was lower (p<0.0001) than all except the Maalox 
group. Groups dosed with water, vitamin C and Bufferin had 
values between aspirin and the two antacids. Animals dosed 
with Bufferin had more (p<0.02) 51 chromium in blood.than 
rats dosed with water and tended (p<O.OS) to be higher than 
rats dosed with vitamin c. Animals dosed with vitamin C and 
water were not different (p>0.50). 
Total cumulative urinary 51 chromium after intubation 
was higher (p<0.004) in the aspirin group than with any 
other test substance, at all intervals and lower (p<0.02) in 
the Maalox group at 6 and 12 h (Figure 2). Vitamin C and 
Bufferin groups were not significantly different from each 
other, but were higher than Turns at all intervals. At 12 h, 
Slchromium excretion of rats dosed with vitamin c was higher 
than those dosed with water, Turns or Maalox. 
Twelve hours after dosing, 51 chromium was significantly 
higher in liver, kidney and spleen in the aspirin group than 
any other group (Figure 3). In liver, rats dosed with the 
Bufferin had more Slchromium than rats dosed with Turns 
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(p<0.03) or Maalox (p<0.003). In kidney, Bufferin was 
higher than water (p<0.02), Turns (p<0.004) and Maalox 
(p<O.OOOl). In spleen, all groups were significantly higher 
than Maalox but were not significantly different from each 
other. 
In all other tissues sampled [(brain, heart, bone 
(Figure 4) and eye, ovaries and fallopian tube (Figure 5)], 
51chromium was significantly higher in the aspirin group. 
In brain, eye and fallopian tubes there were no significant 
differences between the other groups. In heart and bone 
(Figure 4) and ovaries (Figure 5), the groups dosed with 
Maalox tended to be lower than all other groups. The other 
groups were not significantly different from each other. 
DISCUSSION 
Chromium precipitates in the form of large, insoluble 
complexes at the alkaline pH of the intestine. Therefore 
chromium absorption may depend on the efficiency with which 
suitable ligands protect against complex formation (22). 
Vitamin c is known to enhance iron absorption by forming 
soluble-monomeric complexes that prevent precipitation and 
polymerization (43). The enhancement of calcium absorption 
by vitamin c occurs in a similar manner. In this study, the 
increased absorption of 51cr in the vitamin c group compared 
with the antacid groups, may be due to 51 cr binding to 
vitamin c thereby protecting against precipitation and 
olation. Thus, the increased absorption could be due to the 
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formation of soluble complexes rather than merely an effect 
of low pH. 
Antacids influence drug or mineral absorption by 
alteration of ionization state or solubility factors 
dependent on pH. Antacids also delay gastric emptying and 
can chelate or adsorb susceptible products. The solubility 
product of a mineral depends upon the fact that largely 
insoluble mineral hydroxides form as pH is increased and are 
in equilibrium with the metal ion at any given pH. An 
increase in pH or ·(OH-), causes a decrease in the free metal 
ion. For instance, iron, like other minerals from the 
transition series, does not exist in water as an ion but as 
a hydrate. As the pH is raised the mineral hydrates tend to 
lose protons and form less soluble hydroxides (23). Thus, 
the increased pH caused by both Maalox and Tums may be 
partially responsible for the decreased absorption of Slcr. 
However, absorption and metabolism of chromium are also 
affected by interactions with other metals, especially zinc 
and iron (20, 24) 
The effects of antacids on mineral absorption depend on 
their components. Freeman and Ivy (11) reported that the 
utilization of dietary iron was reduced in anemic rats when 
antacids containing calcium carbonate or aluminum hydroxide 
were administered. Hall and Davis (19) found that the 
addition of magnesium trisilicate to a dose of 5 mg of iron 
as a solution of ferrous sulfate significantly reduced iron 
absorption. Ekenved and colleagues (12) also reported a 
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significant decrease in the absorption of iron from ferrous 
sulfate tablets when administered simultaneously with an 
antacid suspension containing a mixture of aluminum 
hydroxide, magnesium hydroxide and magnesium carbonate. 
This decreased absorption also was explained by a formation 
of insoluble iron salts at the higher gastric pH induced by 
the antacids. However another recent report indicated that 
pH was not the major factor affecting iron absorption (25). 
A therapeutic dose of liquid antacid containing aluminum 
hydroxide and magnesium hydroxide had little or no effect on 
absorption of iron from ferrous sulfate in mildly iron-
deficient adults. When the same iron deficient subjects 
ingested calcium carbonate or sodium bicarbonate with the 
iron dose, iron absorption was significantly reduced but not 
totally inhibited. The effect of the carbonates depended 
more on the formation of insoluble iron-carbonates than on 
pH. 
In the present study, chromium absorption was lower in 
the group intubated with the antacid containing aluminum 
hydroxide and magnesium hydroxide (Maalox) than in the group 
receiving the calcium carbonate antacid (Tums). While 
chromium does seem to be partially dependent on pH for 
absorption, other factors may contribute as well to the 
effect seen with antacids. 
Action of antacids on the gastric mucosa is far more 
general and complex than simple luminal acid neutralization 
and binding of pepsin. szelenyi et al. (26) demonstrated 
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that aluminum hydroxide or its combination with calcium 
carbonate reduced both hydrogen back diffusion and sodium 
influx and prevented a fall in potential diffusion induced 
by taurocholate. Calcium carbonate alone was ineffective. 
The observed cytoprotective effect of aluminum hydroxide 
containing antacids was hypothesized to be linked to 
prostaglandins. Berstad and coauthors (27) reported 
incr.eased intraluminal concentrations of PGE2 in response to 
intragastric administration of both high and low doses of 
aluminum hydroxide and aluminum hydroxide containing 
antacids. The increase in PGE2 was greater with the high 
dose of aluminum hydroxide alone than when it was given in 
an antacid mixture together with magnesium hydroxide and 
calcium carbonate. Tarnawski and colleagues (28) reported 
increased mucus discharge in areas where aluminum hydroxide 
containing antacid crystals adhered to the mucosal surface. 
These aluminum hydroxide containing antacids induced an 
increase in hydrogen secretion, potassium and osmolality of 
gastric contents and increased luminal concentration and 
release of PGE2 by 5-20 times (p<O.Ol) over controls. Many 
studies have shown that PGE2 was effective in preventing the 
gastrointestinal blood loss induced by acetylsalicylic acid 
(aspirin) in healthy volunteers (29-30). Acetylsalicylic 
acid induced gastric bleeding was also decreased in the 
presence of PGE2 in healthy volunteers (31-33). 
Furthermore, several studies have shown that 
prostaglandins protect the gastric mucosal barrier by 
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tightening the mucosal barrier. They thereby prevented 
gastric alterations (increased fluxes of hydrogen, sodium, 
and potassium, decreased transmucosal electrical potential, 
and increased pepsin secretion) produced by intragastric 
administration of aspirin in both rats and dogs (34-36). The 
cytoprotection resulting from "tightening" of the gastric 
mucosal barrier may have decreased absorption of Slcr in the 
group receiving Maalox (aluminum hydroxide and magnesium 
hydroxide combination antacid) in our study. 
Aspirin damages the gastric mucosa following oral 
administration in the non-ionized form (37). However, the 
underlying mechanism responsible for an increase in mucosal 
permeability and formation of hemorrhagic erosions remains 
unclear. A theoretical model proposes that gastric toxicity 
is due primarily to accumulation of drug anions in the 
surface mucosal cells. in the normally acidic gastric 
lumen, aspirin is predominantly un-ionized and therefore 
rapidly absorbed but on entering the neutral environment of 
the mucosal cells the drug becomes ionized and is trapped. 
It is possible that dissociation of the acid may disturb the 
internal osmotic stability and buffer system of the cell, 
while the high concentration of anions may interfere with 
intracellular metabolism (37, 38). 
Clinical and physiological investigations have clearly 
shown that aspirin injures the gastric mucosa. 
Physiologically, the damage results in sharp increases in 
the movement of tissue electrolytes, larger molecules 
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(including DNA), and even epithelial cells into the gastric 
lumen. Changes in mucous, potential difference, and blood 
flow have also been associated with aspirin intake (37). 
Davenport has postulated the existence of a number of 
gastrointestinal barriers. These include barriers for 
electrolyte flux, protein loss, and red cell movement (39). 
Epithelial cells of the gastric mucosa, like other cells, 
have a lipid and protein layer penetrated by water-filled 
channels. This layer links adjacent cells by so-called 
tight junctions at their surface. Water, electrolytes, and 
water-soluble drugs such as glucose and urea can enter the 
mucosal surface through these "pores". 
Fat~soluble compounds on the other hand, cross the 
membrane by dissolving in the lipid. Acetylsalicylic acid 
is relatively lipid-soluble in the un-ionized state, and at 
pH 1 can penetrate the gastric mucosa. Increased absorption 
of hydrogen ions follows, producing in turn greater mucosal 
damage. At the same time more sodium ions move into the 
gastric lumen. Alterations of mucosal permeability occur 
thereby allowing greater absorption of aspirin via a leaky 
gastric mucosal barrier (40). 
Despite almost 100 years of widespread use, the mode of 
action of aspirin and several other OTC analgesics is not 
accepted unequivocally. Aspirin is a relatively potent 
inhibitor of prostaglandin synthesis and shows signs of 
ccumulation in inflamed tissues, the wall of the 
gastrointestinal tract, the kidney, liver, blood and bone 
33 
marrow. Hence, it has been assumed that inhibition of 
prostaglandin synthesis in these body compartments is the 
most important molecular mode of action (41-42). However, 
further study is needed. 
In our study, absorption of Slchromium was 
significantly higher in the aspirin group than in the 
vitamin C group. This increased absorption of Slchromium in 
the aspirin group does not appear to be strictly pH related, 
because the pH of vitamin c was 2.76, while the pH of 
aspirin was 2.74. Furthermore, Slchromium absorption and 
retention in the Bufferin group (pH 8.73) tended to be 
higher in blood (p<0.08) (Figure 1), and higher in liver and 
kidney (p<0.11) (Figure 3) than the vitamin c group. The pH 
of Bufferin (pH 8.73), Tums (pH 9.72) and Maalox (pH 8.39) 
-
was similar. Thus, the differences in absorption and 
retention can not be explained by pH alone. Slchromium 
absorption may be influenced by chelation or acetylation by 
aspirin or possibly by prostaglandin inhibition. 
Measurement of prostaglandins, plasma proteins, glucose, and 
salicylate metabolites would provide important information 
on the specific mechanisms involved in chromium absorption, 
retention and excretion. 
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
Summary 
Forty-six female Sprague Dawley rats (mean weight 278±5 
grams) were randomly assigned to six treatment groups. In 
addition to the control group given distilled water, groups 
were given Tums, Maalox, vitamin c, aspirin or Bufferin. 
After a twelve hour fast, the drugs were administered by 
gastric intubation followed immediately by an oral dose of 
51crcl3. Blood, urine and tissues were sampled and counted 
in a gamma counter to assess 5lchromium chloride absorption, 
retention and excretion. 
5lchromium in blood, urine and tissues was higher 
(p<O.OOOl) in the aspirin group than in other groups. The 
group given Maalox had lower (p<O.OOOl) 51chromium in blood, 
urine and tissues than the other groups. The Tums group was 
lower than all except the Maalox group. Groups dosed with 
water, vitamin C and Bufferin had values between aspirin and 
the two antacids. 
Conclusions 
The objective of the study was to determine if selected 
over-the-counter drugs (Tums, Maalox, vitamin c, aspirin or 
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Bufferin) alter absorption, retention or urinary excretion 
of 51cr from 51crcl3 in female rats. Based on the results 
of these analyses the following conclusions were reached. 
Hypothesis 
There will be no statistically significant differences 
in absorption, retention or excretion of 51chromium from 
51crc13 due to a dose of distilled water, Tums, Maalox, 
vitamin c, aspirin or Bufferin. 
The hypothesis was rejected. There were significant 
differences in absorption, retention and excretion of 
Slchromium from 5lcrcl3 after dosing with Tums, Maalox, 
vitamin c, aspirin or Bufferin. 
Recommendations 
The following recommendations for future research were 
developed from this study. While the effects of single-
dosing of over-the-counter drugs on chromium metabolism may 
be generalizable to infrequent self-medication for 
occasional pain or discomfort, long term studies with 
therapeutic dosing are needed to evaluate the effects of 
their chronic use on chromium metabolism. The measurement 
of prostaglandins may provide more insight into the possible 
mechanisms influencing the pharmacodynamics of drugs and 
their interactions with chromium. Salicylate measurement, 
creatine clearance, glucose and plasma protein measurements 
are all parameters worthy of investigation. 
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TABLE 1 
Effects of Over-the-Counter Drugs on 51cr in Blood at 
Various Times after Dosingl,2 
-
Time 
Drug n 45 min 1. 5 hr 3 hr 6 hr 
% of Dose 
Water 8 0.073±0.018b 0.075±0.018b 0.066±0.014b 0.053±0.0llbc 
Turns 9 0.029±0.006b 0.030±0.006b 0.031±0.0Q5C 0.029±0.0Q5C 
ttaalox 8 0.010±0.007C O.Ol6:!0.007C 0.016±0.006d 0.012±0.003d 
Vitamin C 8 0.079±0.023b 0.090±0.024b 0.086±0.023b 0.071±0.019b 
Aspirin 6 2.974±0.792a 2.312±0.743a 2.070±0.53oa 1.572±0.365a 
Bufferi n 7 0.142±0.052b 0.143±0.055b 0.128±0.05Qb 0. 105·± 0. 038b 
lf1e a n ± SEt~ . 
2t1eans not sharing a common superscript are significantly different (p<0.05). 
12 hr 
0.041±0.009b 
0.023±0.004b 
0.008±0.003C 
0.050± 0.012b 
1.038± 0. 215a 
0.081±0.024b 
U1 
U1 
nrug n 
Water 8 
Tums 9 
ttaalox 8 
Vitamin C 8 
Aspf ri n 6 
Bufferi n 7 
lrtean ± SErt. 
TABLE 2 
Effects of Over-the-Counter Drugs on Total 5lcr 
in llrine at 3, 6, and 12 Hours after nosingl ,2 
Time 
-
3 hr 6 hr 
% of Dose 
0.045±0.012bc 0.089±0,}2]Cd 
0.020t0.005Cd 0,052t0.010d 
o.omHo.ooJd 0.018±0.006e 
0.07810.017b O.l95±0.042b 
0.518±0.17la l.029±0.317a 
0.064J0.019b 0.152±0.0J3bc 
2t1eans not sharing a common superscript are s1gn1ficimtly different (p<0.05). 
12 lu· 
O.ll9.t0.028cd 
0.119t0.042d 
0.027J0.009e 
0.286±0.055b 
1.528±0.357a 
0. 221!0,040bC 
(.j1 
0> 
TABLE 3 
lfFerts of Over-lltt!-f.tHIIIlel~nruqs on ~dcr In Thsues 
12 !lours after LJosinq1,2 
--·- ------ - -· 
llruq n l.i ve r Kidney 
---- -----
% of·Oose 
Uater B O.OOU9t0.001Bhc 0.0063:tO.OOIOC 
Turns 9 0.0051±0.00Q9C 0.0045±0.000fiCd 
t1aalox B O.OOJO!O.OOllc 0.0015.t0.0006d 
Vitamin C 8 O.OOU3t0.0020bc 0.0097±0.002Bbc 
Aspirin 6 O.l697.!0.035Ua O.J240t0.0214a 
Bufferi n 7 0. OJ 76 !0. 0042b 0.0174±0.0046b 
·1r1ean ± SEt1. 
2neans not sharinq a common superscript are sl~nificantly different {p<0.05). 
Spleen 
O.OOOBtO.OOOJb 
0.0007±0.000)b 
0. 0004±0. 0001 b 
0.0008±0.0002h 
O.Ol99!0.0060il 
0.0009t0.0002b 
<.n 
-......! 
Ort!9 n 
Water 8 
Turns 9 
r1aalox 8 
Vi tamrn c 8 
Aspfrfn 6 
Bufferi n 7 
TABLE 4 
Effects of Over-the-Counter Orugs on 51cr in Tissues 
12 llours after llosingl,2 
Brain lluart 
% Dose % Oose 
0.0006±0.0003b 0.0018t0.0004b 
0.0003±0.000lb 0.0008±0.0002bc 
0.0003±0.000lb 0.0005±0.0002C 
0.0002tO.OOOJb 0.0009J.0.0003hc 
0.0025:t0.0004a 0.0162t0.002fia 
n. non 3 w. ooo l b o. 001010. onnJbc 
----------------- -·----·----~-----------------------·--------· 
lf1ean ± SEtL 
2t1eans not sharing a common superscript are sf~1nlffcanlly different (p<0 .. 05). 
Bone 
-
% Dose/g 
0. 0017±0. 0004b 
0. 00 lO.tO. 0002bc 
0.000410.0001c 
0. 0017 :!0. 0004hc 
0.026510.0050<1 
0.0022!0.0006b 
(J1 
(X) 
TABLE 5 
Effects of Over-the-Counter Drugs on 51cr in Tissues 
. 12 !lours after Dosingl,2 
Drug n Eye Ovaries Fdllopian luhe 
- -
-----------------------------------------
% nose 
Hater 8 0.00015±0.00006b 0.0002610.00005bc 0.00040!0.00007b 
Turns 9 0.0002110.00010b 0.00015±0.00006bc 0.00019!0.00004b 
rtaalox 8 0.0000510.00003b 0.00008i0.00004C 0.000l4!0.00005b 
Vitamin C 8 0.00006±0.00003b 0.00024±0.00010bc 0.00025i0.00008b 
/\spirin 6 0.00079t0.00013a 0.0039710.00085a 0.0079110.00235a 
Bufferin 7 0.00002t0.00002b 0.00042!0.00013b 0.0009310.00054b 
lrtean ± SH1. 
2neans not sharin9 a common superscript are sinnificantly different (p<0.05). tTl \0 
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